PharmaSurgics patented drug candidate PXL01, has demonstrated an excellent effect and safety profile in preclinical studies and the first clinical trial on patients are planned to start in the end of 2009.
PharmaSurgics goal is to be first to market with a pharmacological product for the prevention of post-surgical adhesions.